1
|
Sarkar A, Paul A, Banerjee T, Maji A, Saha S, Bishayee A, Maity TK. Therapeutic advancements in targeting BCL-2 family proteins by epigenetic regulators, natural, and synthetic agents in cancer. Eur J Pharmacol 2023; 944:175588. [PMID: 36791843 DOI: 10.1016/j.ejphar.2023.175588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2022] [Revised: 01/21/2023] [Accepted: 02/08/2023] [Indexed: 02/17/2023]
Abstract
Cancer is amongst the deadliest and most disruptive disorders, having a much higher death rate than other diseases worldwide. Human cancer rates continue to rise, thereby posing the most significant concerns for medical health professionals. In the last two decades, researchers have gone past several milestones in tackling cancer while gaining insight into the role of apoptosis in cancer or targeting various biomarker tools for prognosis and diagnosis. Apoptosis which is still a topic full of complexities, can be controlled considerably by B-cell lymphoma 2 (BCL-2) and its family members. Therefore, targeting proteins of this family to prevent tumorigenesis, is essential to focus on the pharmacological features of the anti-apoptotic and pro-apoptotic members, which will help to develop and manage this disorder. This review deals with the advancements of various epigenetic regulators to target BCL-2 family proteins, including the mechanism of several microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Similarly, a rise in natural and synthetic molecules' research over the last two decades has allowed us to acquire insights into understanding and managing the transcriptional alterations that have led to apoptosis and treating various neoplastic diseases. Furthermore, several inhibitors targeting anti-apoptotic proteins and inducers or activators targeting pro-apoptotic proteins in preclinical and clinical stages have been summarized. Overall, agonistic and antagonistic mechanisms of BCL-2 family proteins conciliated by epigenetic regulators, natural and synthetic agents have proven to be an excellent choice in developing cancer therapeutics.
Collapse
Affiliation(s)
- Arnab Sarkar
- Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700032, India.
| | - Abhik Paul
- Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700032, India.
| | - Tanmoy Banerjee
- Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700032, India.
| | - Avik Maji
- Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700032, India.
| | - Sanjukta Saha
- Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700032, India.
| | - Anupam Bishayee
- College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL, 34211, USA.
| | - Tapan Kumar Maity
- Department of Pharmaceutical Technology, Jadavpur University, West Bengal, Kolkata, 700032, India.
| |
Collapse
|
2
|
Liu W, Jiang J, Lin Y, You Q, Wang L. Insight into Thermodynamic and Kinetic Profiles in Small-Molecule Optimization. J Med Chem 2022; 65:10809-10847. [PMID: 35969687 DOI: 10.1021/acs.jmedchem.2c00682] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Structure-activity relationships (SARs) and structure-property relationships (SPRs) have been considered the most important factors during the drug optimization process. For medicinal chemists, improvements in the potencies and druglike properties of small molecules are regarded as their major goals. Among them, the binding affinity and selectivity of small molecules on their targets are the most important indicators. In recent years, there has been growing interest in using thermodynamic and kinetic profiles to analyze ligand-receptor interactions, which could provide not only binding affinities but also detailed binding parameters for small-molecule optimization. In this perspective, we are trying to provide an insight into thermodynamic and kinetic profiles in small-molecule optimization. Through a highlight of strategies on the small-molecule optimization with specific cases, we aim to put forward the importance of structure-thermodynamic relationships (STRs) and structure-kinetic relationships (SKRs), which could provide more guidance to find safe and effective small-molecule drugs.
Collapse
Affiliation(s)
- Wei Liu
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.,Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
| | - Jingsheng Jiang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | - Yating Lin
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.,Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
| | - Qidong You
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.,Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
| | - Lei Wang
- State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.,Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
| |
Collapse
|
3
|
What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy? Cell Death Differ 2022; 29:1079-1093. [PMID: 35388168 DOI: 10.1038/s41418-022-00987-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Revised: 03/04/2022] [Accepted: 03/15/2022] [Indexed: 12/21/2022] Open
Abstract
In many human cancers the control of apoptosis is dysregulated, for instance as a result of the overexpression of pro-survival BCL-2 proteins. This promotes tumorigenesis by protecting nascent neoplastic cells from stress and renders malignant cells resistant to anti-cancer agents. Therefore, several BH3 mimetic drugs targeting distinct pro-survival proteins have been developed. The BCL-2 inhibitor Venetoclax/ABT-199, has been approved for treatment of certain blood cancers and tens of thousands of patients have already been treated effectively with this drug. To advance the clinical development of MCL-1 and BCL-XL inhibitors, a more detailed understanding of their distinct and overlapping roles in the survival of malignant as well as non-transformed cells in healthy tissues is required. Here, we discuss similarities and differences in pro-survival BCL-2 protein structure, subcellular localisation and binding affinities to the pro-apoptotic BCL-2 family members. We summarise the findings from gene-targeting studies in mice to discuss the specific roles of distinct pro-survival BCL-2 family members during embryogenesis and the survival of non-transformed cells in healthy tissues in adults. Finally, we elaborate how these findings align with or differ from the observations from the clinical development and use of BH3 mimetic drugs targeting different pro-survival BCL-2 proteins.
Collapse
|
4
|
Hwang HJ, Kim JS, Lee J, Min JS, Jeong KB, Kim E, Lee MK, Chi SW. Single-Molecule Sensing of an Anticancer Therapeutic Protein-Protein Interaction Using the Chemically Modified OmpG Nanopore. Anal Chem 2022; 94:7449-7454. [PMID: 35583342 DOI: 10.1021/acs.analchem.1c04840] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Nanopore sensors are a highly attractive platform for single-molecule sensing for sequencing, disease diagnostics, and drug screening. Outer membrane protein G (OmpG) nanopores have advantages for single-molecule sensing owing to their rigid monomeric structure, which comprises seven flexible loops, providing distinct gating patterns upon analyte binding. Blocking of the protein-protein interaction between B-cell lymphoma-extra-large (Bcl-xL) and the BH3 domain of Bcl-2 homologous antagonist/killer (Bak-BH3) has been reported as a promising strategy for anticancer therapy. Here, we characterized the interaction between Bcl-xL and Bak-BH3 as well as its inhibition by a small-molecule inhibitor using click chemistry-based Bak-BH3 peptide-conjugated OmpG nanopores. The binding of Bcl-xL to Bak-BH3 generated characteristic gating signals involving significant changes in the amplitudes of noise and gating parameters such as gating frequency, open probability, and durations of open and closed states. Notably, specific inhibition of Bcl-xL by the small-molecule antagonist, ABT-737, led to the recovery of the noise and gating parameters. Collectively, these results revealed that the chemically modified OmpG nanopore can serve as a valuable sensor platform for ultrasensitive, rapid, and single-molecule-based drug screening against protein-protein interactions, which are therapeutic targets for various diseases.
Collapse
Affiliation(s)
- Hye-Jin Hwang
- Disease Target Structure Research Center, Division of Biomedical Research, KRIBB, Daejeon 34141, Republic of Korea.,Department of Proteome Structural Biology, KRIBB School of Bioscience, University of Science and Technology, Daejeon 34113, Republic of Korea
| | - Jin-Sik Kim
- Disease Target Structure Research Center, Division of Biomedical Research, KRIBB, Daejeon 34141, Republic of Korea
| | - Jeonghyun Lee
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea
| | - Jun Sik Min
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea
| | - Ki-Baek Jeong
- Disease Target Structure Research Center, Division of Biomedical Research, KRIBB, Daejeon 34141, Republic of Korea
| | - Eunha Kim
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea
| | - Mi-Kyung Lee
- Disease Target Structure Research Center, Division of Biomedical Research, KRIBB, Daejeon 34141, Republic of Korea.,Department of Proteome Structural Biology, KRIBB School of Bioscience, University of Science and Technology, Daejeon 34113, Republic of Korea
| | - Seung-Wook Chi
- Disease Target Structure Research Center, Division of Biomedical Research, KRIBB, Daejeon 34141, Republic of Korea.,Department of Proteome Structural Biology, KRIBB School of Bioscience, University of Science and Technology, Daejeon 34113, Republic of Korea
| |
Collapse
|
5
|
Trometer N, Roignant M, Davioud-Charvet E. Efficient Multigram-Scale Synthesis of 7-Substituted 3-Methyltetral-1-ones and 6-Fluoromenadione. Org Process Res Dev 2022. [DOI: 10.1021/acs.oprd.1c00421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Nathan Trometer
- Laboratoire dʼInnovation Moléculaire et Applications (LIMA), Team Bio(IN)organic and Medicinal Chemistry, European School of Chemistry, Polymers and Materials (ECPM), UMR7042 Université de Strasbourg−CNRS−UHA, 25 Rue Becquerel, Strasbourg 67087, France
| | - Matthieu Roignant
- Laboratoire dʼInnovation Moléculaire et Applications (LIMA), Team Bio(IN)organic and Medicinal Chemistry, European School of Chemistry, Polymers and Materials (ECPM), UMR7042 Université de Strasbourg−CNRS−UHA, 25 Rue Becquerel, Strasbourg 67087, France
| | - Elisabeth Davioud-Charvet
- Laboratoire dʼInnovation Moléculaire et Applications (LIMA), Team Bio(IN)organic and Medicinal Chemistry, European School of Chemistry, Polymers and Materials (ECPM), UMR7042 Université de Strasbourg−CNRS−UHA, 25 Rue Becquerel, Strasbourg 67087, France
| |
Collapse
|
6
|
Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer 2022; 22:45-64. [PMID: 34663943 DOI: 10.1038/s41568-021-00407-4] [Citation(s) in RCA: 116] [Impact Index Per Article: 58.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/02/2021] [Indexed: 12/14/2022]
Abstract
Apoptosis is a form of programmed cell death that is regulated by the balance between prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a hallmark of cancer that arises when this balance is tipped in favour of survival. One form of anticancer therapeutic, termed 'BH3-mimetic drugs', has been developed to directly activate the apoptosis machinery in malignant cells. These drugs bind to and inhibit specific prosurvival BCL-2 family proteins, thereby mimicking their interaction with the BH3 domains of proapoptotic BCL-2 family proteins. The BCL-2-specific inhibitor venetoclax is approved by the US Food and Drug Administration and many regulatory authorities worldwide for the treatment of chronic lymphocytic leukaemia and acute myeloid leukaemia. BH3-mimetic drugs targeting other BCL-2 prosurvival proteins have been tested in preclinical models of cancer, and drugs targeting MCL-1 or BCL-XL have advanced into phase I clinical trials for certain cancers. As with all therapeutics, efficacy and tolerability need to be carefully balanced to achieve a therapeutic window whereby there is significant anticancer activity with an acceptable safety profile. In this Review, we outline the current state of BH3-mimetic drugs targeting various prosurvival BCL-2 family proteins and discuss emerging data regarding primary and acquired resistance to these agents and approaches that may overcome this. We highlight issues that need to be addressed to further advance the clinical application of BH3-mimetic drugs, both alone and in combination with additional anticancer agents (for example, standard chemotherapeutic drugs or inhibitors of oncogenic kinases), for improved responses in patients with cancer.
Collapse
Affiliation(s)
- Sarah T Diepstraten
- The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia
| | - Mary Ann Anderson
- The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia
- Department of Clinical Haematology, Royal Melbourne Hospital, Melbourne, VIC, Australia
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Peter E Czabotar
- The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia
| | - Guillaume Lessene
- The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia
- Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, VIC, Australia
| | - Andreas Strasser
- The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
- Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
| | - Gemma L Kelly
- The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
- Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
| |
Collapse
|
7
|
Yurttaş L, Temel HE, Aksoy MO, Bülbül EF, Çiftçi GA. New chromanone derivatives containing thiazoles: Synthesis and antitumor activity evaluation on A549 lung cancer cell line. Drug Dev Res 2021; 83:470-484. [PMID: 34532880 DOI: 10.1002/ddr.21879] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 08/23/2021] [Accepted: 08/26/2021] [Indexed: 01/05/2023]
Abstract
Novel 2-[2-(chroman-4-ylidene)hydrazinyl]-4/5-substituted thiazole derivatives (2a-i) were synthesized and investigated for their anticancer activity. Cytotoxic activity on A549 and NIH/3T3 cell lines was determined, most of the compounds exhibited high cytotoxic profile with selectivity. Selected compounds 2b, 2c, 2e, 2g, 2h, and 2i were tested to determine induction of apoptosis, mitochondrial membrane depolarization, and cell cycle arrest. The results showed that the compounds induced apoptosis intrinsically that they triggered loss of mitochondrial potential through increasing the accumulation of cells in G2/M. Besides, intrinsic apoptotic pathway was supported by down-regulation of anti-apoptotic protein Bcl-2 and up-regulation of proapoptotic protein Bax. Molecular docking study for compounds 2b, 2c, and 2g was promoted experimental outcomes.
Collapse
Affiliation(s)
- Leyla Yurttaş
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey
| | - Halide Edip Temel
- Department of Biochemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey
| | - Mehmet Onur Aksoy
- Department of Biochemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey
| | - Emre Fatih Bülbül
- Institute of Pharmacy, Martin Luther University of Halle-Wittenberg, Halle/Saale, Germany
| | - Gülşen Akalin Çiftçi
- Department of Biochemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey
| |
Collapse
|
8
|
Chen W, Li J. Alternative splicing of BCL-X and implications for treating hematological malignancies. Oncol Lett 2021; 22:670. [PMID: 34345295 PMCID: PMC8323006 DOI: 10.3892/ol.2021.12931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Accepted: 05/19/2021] [Indexed: 11/16/2022] Open
Abstract
BCL-X is a member of the BCL-2 family. It regulates apoptosis and plays a critical role in hematological malignancies. It is well-known that >90% of human genes undergo alternative splicing. A total of 10 distinct splicing transcripts of the BCL-X gene have been identified, including transcript variants 1–9 and ABALON. Different transcripts from the same gene have different functions. The present review discusses the progress in understanding the different alternative splicing transcripts of BCL-X, including their characteristics, functions and expression patterns. The potential use of BCL-X in targeted therapies for hematological malignancies is also discussed.
Collapse
Affiliation(s)
- Wanling Chen
- Department of Clinical Medicine, Xiamen Medical College, Xiamen, Fujian 361023, P.R. China
| | - Jinggang Li
- Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China
| |
Collapse
|
9
|
Tao ZF, Wang X, Chen J, Ingram JP, Jin S, Judge RA, Kovar PJ, Park C, Sun C, Wakefield BD, Zhou L, Zhang H, Elmore SW, Phillips DC, Judd AS, Leverson JD, Souers AJ. Structure-Based Design of A-1293102, a Potent and Selective BCL-X L Inhibitor. ACS Med Chem Lett 2021; 12:1011-1016. [PMID: 34141086 PMCID: PMC8201748 DOI: 10.1021/acsmedchemlett.1c00162] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Accepted: 05/07/2021] [Indexed: 01/10/2023] Open
Abstract
BCL-XL, an antiapoptotic member of the BCL-2 family of proteins, drives tumor survival and maintenance and thus represents a key target for cancer treatment. Herein we report the rational design of a novel series of selective BCL-XL inhibitors exemplified by A-1293102. This molecule contains structural elements of selective BCL-XL inhibitor A-1155463 and the dual BCL-XL/BCL-2 inhibitors ABT-737 and navitoclax, while representing a distinct pharmacophore as assessed by an objective cheminformatic evaluation. A-1293102 exhibited picomolar binding affinity to BCL-XL and both efficiently and selectively killed BCL-XL-dependent tumor cells. X-ray crystallographic analysis demonstrated a key hydrogen bonding network in the P2 binding pocket of BCL-XL, while the bent-back moiety achieved efficient occupancy of the P4 pocket in a manner similar to that of navitoclax. A-1293102 represents one of the few distinct structural series of selective BCL-XL inhibitors, and thus serves as a useful tool for biological studies as well as a lead compound for further optimization.
Collapse
Affiliation(s)
- Zhi-Fu Tao
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Xilu Wang
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Jun Chen
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Justin P. Ingram
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Sha Jin
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Russell A. Judge
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Peter J. Kovar
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Chang Park
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Chaohong Sun
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Brian D. Wakefield
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Li Zhou
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Haichao Zhang
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Steven W. Elmore
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Darren C. Phillips
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Andrew S. Judd
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Joel D. Leverson
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| | - Andrew J. Souers
- AbbVie Inc., 1 North Waukegan Rd, North
Chicago, Illinois 60064, United States
| |
Collapse
|
10
|
Nguyen W, Lee EF, Evangelista M, Lee M, Harris TJ, Colman PM, Smith NA, Williams LB, Jarman KE, Lowes KN, Haeberli C, Keiser J, Smith BJ, Fairlie WD, Sleebs BE. Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2. ACS Infect Dis 2021; 7:1143-1163. [PMID: 33523649 DOI: 10.1021/acsinfecdis.0c00700] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Limited therapeutic options are available for the treatment of human schistosomiasis caused by the parasitic Schistosoma flatworm. The B cell lymphoma-2 (BCL-2)-regulated apoptotic cell death pathway in schistosomes was recently characterized and shown to share similarities with the intrinsic apoptosis pathway in humans. Here, we exploit structural differences in the human and schistosome BCL-2 (sBCL-2) pro-survival proteins toward a novel treatment strategy for schistosomiasis. The benzothiazole hydrazone scaffold previously employed to target human BCL-XL was repurposed as a starting point to target sBCL-2. We utilized X-ray structural data to inform optimization and then applied a scaffold-hop strategy to identify the 5-carboxamide thiazole hydrazone scaffold (43) with potent sBCL-2 activity (IC50 30 nM). Human BCL-XL potency (IC50 13 nM) was inadvertently preserved during the optimization process. The lead analogues from this study exhibit on-target activity in model fibroblast cell lines dependent on either sBCL-2 or human BCL-XL for survival. Further optimization of the thiazole hydrazone class is required to exhibit activity in schistosomes and enhance the potential of this strategy for treating schistosomiasis.
Collapse
Affiliation(s)
- William Nguyen
- The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville 3010, Australia
| | - Erinna F. Lee
- La Trobe Institute for Molecular Science, La Trobe University, Melbourne 3086, Australia
- Olivia Newton-John Cancer Research Institute, Heidelberg 3084, Australia
- School of Cancer Medicine, La Trobe University, Melbourne 3086, Australia
| | - Marco Evangelista
- Olivia Newton-John Cancer Research Institute, Heidelberg 3084, Australia
| | - Mihwa Lee
- La Trobe Institute for Molecular Science, La Trobe University, Melbourne 3086, Australia
| | - Tiffany J. Harris
- Olivia Newton-John Cancer Research Institute, Heidelberg 3084, Australia
| | - Peter M. Colman
- The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville 3010, Australia
| | - Nicholas A. Smith
- La Trobe Institute for Molecular Science, La Trobe University, Melbourne 3086, Australia
| | - Luke B. Williams
- The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia
| | - Kate E. Jarman
- The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville 3010, Australia
| | - Kym N. Lowes
- The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville 3010, Australia
| | - Cécile Haeberli
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel 4002, Switzerland
- University of Basel, Basel 4001, Switzerland
| | - Jennifer Keiser
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel 4002, Switzerland
- University of Basel, Basel 4001, Switzerland
| | - Brian J. Smith
- La Trobe Institute for Molecular Science, La Trobe University, Melbourne 3086, Australia
| | - W. Douglas Fairlie
- La Trobe Institute for Molecular Science, La Trobe University, Melbourne 3086, Australia
- Olivia Newton-John Cancer Research Institute, Heidelberg 3084, Australia
- School of Cancer Medicine, La Trobe University, Melbourne 3086, Australia
| | - Brad E. Sleebs
- The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville 3010, Australia
- Department of Veterinary Biosciences, The University of Melbourne, Parkville 3010, Australia
| |
Collapse
|
11
|
Roy MJ, Vom A, Okamoto T, Smith BJ, Birkinshaw RW, Yang H, Abdo H, White CA, Segal D, Huang DCS, Baell JB, Colman PM, Czabotar PE, Lessene G. Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X L and BCL-2. J Med Chem 2021; 64:5447-5469. [PMID: 33904752 DOI: 10.1021/acs.jmedchem.0c01771] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The BCL-2 family of proteins (including the prosurvival proteins BCL-2, BCL-XL, and MCL-1) is an important target for the development of novel anticancer therapeutics. Despite the challenges of targeting protein-protein interaction (PPI) interfaces with small molecules, a number of inhibitors (called BH3 mimetics) have entered the clinic and the BCL-2 inhibitor, ABT-199/venetoclax, is already proving transformative. For BCL-XL, new validated chemical series are desirable. Here, we outline the crystallography-guided development of a structurally distinct series of BCL-XL/BCL-2 inhibitors based on a benzoylurea scaffold, originally proposed as α-helix mimetics. We describe structure-guided exploration of a cryptic "p5" pocket identified in BCL-XL. This work yields novel inhibitors with submicromolar binding, with marked selectivity toward BCL-XL. Extension into the hydrophobic p2 pocket yielded the most potent inhibitor in the series, binding strongly to BCL-XL and BCL-2 (nanomolar-range half-maximal inhibitory concentration (IC50)) and displaying mechanism-based killing in cells engineered to depend on BCL-XL for survival.
Collapse
Affiliation(s)
- Michael J Roy
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Amelia Vom
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Toru Okamoto
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Brian J Smith
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Richard W Birkinshaw
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Hong Yang
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Houda Abdo
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Christine A White
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - David Segal
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
| | - David C S Huang
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Jonathan B Baell
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Peter M Colman
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Peter E Czabotar
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
| | - Guillaume Lessene
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department of Medical Biology, The University of Melbourne, Parkville, VIC 3050, Australia
- Department of Pharmacology and Therapeutics, The University of Melbourne, Parkville, VIC 3050, Australia
| |
Collapse
|
12
|
Baell JB. Personal Accounts of Australian Drug Discovery at the Public–Private Interface. Aust J Chem 2021. [DOI: 10.1071/ch20244] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The public–private interface is a vibrant and invigorating stage for drug discovery and can allow for relatively higher risk but more rewarding research. Although adequate resourcing is a perennial challenge, persistence, optimism, and flexibility will pay dividends and can allow for a thoroughly rewarding career. In this account of chronological research experiences, selected examples are used to support this contention.
Collapse
|
13
|
P. K. A, Paira P. Ruthenium( ii) p-cymene complexes of pyridine-2-carboxaldehyde and 2-amino benzothiazole-based ligands: cytoselective and in vitro live cell imaging agents. NEW J CHEM 2021. [DOI: 10.1039/d0nj04137h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A new class of DNA targeting, highly cytoselective, luminescent Ru(ii)–arene complexes was developed.
Collapse
Affiliation(s)
- Anuja P. K.
- Department of Chemistry
- School of Advanced Sciences
- Vellore Institute of Technology
- Vellore-632014
- India
| | - Priyankar Paira
- Department of Chemistry
- School of Advanced Sciences
- Vellore Institute of Technology
- Vellore-632014
- India
| |
Collapse
|
14
|
Çıkla-Süzgün P, Küçükgüzel ŞG. Recent Advances in Apoptosis: THE Role of Hydrazones. Mini Rev Med Chem 2019; 19:1427-1442. [PMID: 30968776 DOI: 10.2174/1389557519666190410125910] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Revised: 10/17/2018] [Accepted: 10/21/2018] [Indexed: 01/22/2023]
Abstract
The process of programmed cell death in higher eukaryotes (apoptosis), is generally characterized by distinct morphological characteristics and energy-dependent biochemical mechanisms. Apoptosis is considered as a vital component of various processes including normal cell turnover, proper development and functioning of the immune system, hormone-dependent atrophy, embryonic development and chemical-induced cell death. Apoptosis seems to play an important key role in the progression of several human diseases like Alzheimer's disease, Parkinson's disease and many types of cancer. Promotion of apoptosis may be a good approach for the prevention of cancer cell proliferation. In early studies, antitumor compounds have been found to induce the apoptotic process in tumor cells. On the other hand, several hydrazones were reported to have lower toxicity than hydrazides due to the blockage of -NH2 group. Therefore, the design of hydrazones that activate and promote apoptosis is an attractive strategy for the discovery and development of potential anticancer agents. The aim of this review is to provide a general overview of current knowledge and the connection between apoptosis and hydrazone. It is also the guide for the apoptotic activities of new hydrazone derivatives.
Collapse
Affiliation(s)
- Pelin Çıkla-Süzgün
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Haydapaşa, 34668, İstanbul, Turkey
| | - Ş Güniz Küçükgüzel
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Haydapaşa, 34668, İstanbul, Turkey
| |
Collapse
|
15
|
You C, Wu H, Gao Z, Chen F, Ning L, Zhang Y, Dong Y, Sun B, Wang F. Enhanced Reactive Oxygen Species Levels by an Active Benzothiazole Complex-Mediated Fenton Reaction for Highly Effective Antitumor Therapy. Mol Pharm 2019; 16:4929-4939. [DOI: 10.1021/acs.molpharmaceut.9b00819] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Chaoqun You
- College of Chemical Engineering, Nanjing Forestry University; Jiangsu Key Lab for the Chemistry and Utilization of Agro-Forest Biomass, Nanjing 210037, People’s Republic of China
| | - Hongshuai Wu
- School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, People’s Republic of China
| | - Zhiguo Gao
- School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, People’s Republic of China
| | - Fanghui Chen
- School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, People’s Republic of China
| | - Like Ning
- College of Chemical Engineering, Nanjing Forestry University; Jiangsu Key Lab for the Chemistry and Utilization of Agro-Forest Biomass, Nanjing 210037, People’s Republic of China
| | - Yu Zhang
- College of Chemical Engineering, Nanjing Forestry University; Jiangsu Key Lab for the Chemistry and Utilization of Agro-Forest Biomass, Nanjing 210037, People’s Republic of China
| | - Yixin Dong
- College of Chemical Engineering, Nanjing Forestry University; Jiangsu Key Lab for the Chemistry and Utilization of Agro-Forest Biomass, Nanjing 210037, People’s Republic of China
| | - Baiwang Sun
- School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, People’s Republic of China
| | - Fei Wang
- College of Chemical Engineering, Nanjing Forestry University; Jiangsu Key Lab for the Chemistry and Utilization of Agro-Forest Biomass, Nanjing 210037, People’s Republic of China
| |
Collapse
|
16
|
Mor S, Sindhu S, Khatri M, Singh N, Vasudeva N, Panihar N. Synthesis, Type II Diabetes Inhibitory Activity, and Antimicrobial Tests of Benzothiazole Derivatives Bridged with Indenedione by Methylenehydrazone. RUSS J GEN CHEM+ 2019. [DOI: 10.1134/s1070363219090226] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
17
|
Pattarawarapan M, Yamano D, Wiriya N, Phakhodee W. Metal-Free Synthesis of 2- N, N-Dialkylaminobenzoxazoles Using Tertiary Amines as the Nitrogen Source. J Org Chem 2019; 84:6516-6523. [PMID: 31017442 DOI: 10.1021/acs.joc.9b00797] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The unprecedented reaction of tertiary amines with 2(3 H)-benzoxazolones has been investigated. In the presence of the Ph3P-I2 reagent system, the reaction of both acyclic and cyclic aliphatic tertiary amines led to the formation of 2- N, N-dialkylaminobenzoxazoles with the selective cleavage of an alkyl group. Especially, N-(2-iodoethyl)piperazinyl derivatives were rapidly produced in good yields when using DABCO as the nitrogen source. Only in the cases when the nucleophilicity of the substrates exceeds that of the amine, competitive self-condensation of benzoxazolones then proceeds preferentially. 31P{1H}-NMR study suggested the involvement of an aryloxyphosphonium intermediate and/or possibly 2-iodobenzoxazole which activates the C-2 position of benzoxazolones toward nucleophilic aromatic substitution.
Collapse
Affiliation(s)
- Mookda Pattarawarapan
- Department of Chemistry, Faculty of Science , Chiang Mai University , Chiang Mai 50200 , Thailand
- Research Center on Chemistry for Development of Health Promoting Products from Northern Resources, Faculty of Science , Chiang Mai University , Chiang Mai 50200 , Thailand
| | - Dolnapa Yamano
- Department of Chemistry, Faculty of Science , Chiang Mai University , Chiang Mai 50200 , Thailand
| | - Nitaya Wiriya
- Department of Chemistry, Faculty of Science , Chiang Mai University , Chiang Mai 50200 , Thailand
| | - Wong Phakhodee
- Department of Chemistry, Faculty of Science , Chiang Mai University , Chiang Mai 50200 , Thailand
- Research Center on Chemistry for Development of Health Promoting Products from Northern Resources, Faculty of Science , Chiang Mai University , Chiang Mai 50200 , Thailand
| |
Collapse
|
18
|
Anuradha, Patel S, Patle R, Parameswaran P, Jain A, Shard A. Design, computational studies, synthesis and biological evaluation of thiazole-based molecules as anticancer agents. Eur J Pharm Sci 2019; 134:20-30. [PMID: 30965082 DOI: 10.1016/j.ejps.2019.04.005] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2018] [Revised: 03/27/2019] [Accepted: 04/02/2019] [Indexed: 01/04/2023]
Abstract
BACKGROUND Abolition of cancer warrants effective treatment modalities directed towards specific pathways dysregulated in tumor proliferation and survival. The antiapoptotic Bcl-2 proteins are significantly altered in several tumor types which position them as striking targets for therapeutic intervention. Here we designed, computationally evaluated, synthesized, and biologically tested structurally optimized thiazole-based small molecules as anticancer agents. METHODS The virtually designed 200 molecules were subjected to rigorous docking and in silico ADME-Toxicity studies. Out of this, 23 skeletally diverse thiazole-based molecules which passed pan assay interference compounds (PAINS) filter and were synthetically feasible were synthesized in 3 steps using cheap and readily available reagents. The molecules were in vitro evaluated against Bcl-2-Jurkat, A-431 cancerous cell lines and ARPE-19 cell lines. Molecular Dynamics (MD) simulation studies were performed to analyse conformational changes induced by ligand 32 in Bcl-2. Flow cytometry analysis of compound 32 treated Bcl-2 cells was done to check apoptosis. RESULTS The molecules exhibited appreciable interactions with Bcl-2 and were having acceptable drug like properties as tested in silico. The multi step synthesis yielded 23 skeletally diverse thiazole-based molecules in up to 80% yield. The molecules simultaneously inhibited Bcl-2 Jurkat cells in vitro without causing detectable toxicity to normal cells (ARPE-19 cells). Among them molecules 32, 50, 53, 57 and 59 showed considerable activities against Bcl-2 Jurkat and A-431cell lines at concentrations ranging from 32-46 μM and 34-52 μM, respectively. The standard doxorubicin exhibited IC50 in Bcl-2 Jurkat and A-431cell lines at 45.87 μM and 42.37 μM, respectively. The molecule 32, almost equipotent in both the cell lines was subjected to molecular dynamics (MD) simulation with Bcl-2 protein (4IEH). It was shown that 32 interacted with protein majorly via hydrophobic interactions and few H-bonding interactions. Fluorescence-activated cell sorting (FACS) analysis established that molecule is dragging cancerous cells towards apoptosis. DISCUSSION AND CONCLUSION The chemical intuition was checked by computation coupled with biological results confirmed that thiazole-based hits have the potential to be developed downstream into potent and safer leads against antiapoptotic Bcl-2 cells.
Collapse
Affiliation(s)
- Anuradha
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Ahmedabad, Opposite Air Force Station, Gandhinagar, Gujarat, 382355, India
| | - Sagarkumar Patel
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Ahmedabad, Opposite Air Force Station, Gandhinagar, Gujarat, 382355, India
| | - Rajkumar Patle
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Ahmedabad, Opposite Air Force Station, Gandhinagar, Gujarat, 382355, India
| | - Preethi Parameswaran
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Ahmedabad, Opposite Air Force Station, Gandhinagar, Gujarat, 382355, India
| | - Alok Jain
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research Ahmedabad, Opposite Air Force Station, Gandhinagar, Gujarat 382355, India.
| | - Amit Shard
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Ahmedabad, Opposite Air Force Station, Gandhinagar, Gujarat, 382355, India.
| |
Collapse
|
19
|
Jadhav GR, Paira P. Cytotoxic 2‐(2′‐Hydroxyphenyl)benzothiazolylquinoline Analogues and their
In Vitro
Screening through Developmental Assays
†. ChemistrySelect 2019. [DOI: 10.1002/slct.201803618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Gajanan Raosaheb Jadhav
- Department of ChemistrySchool of Advanced SciencesVellore Institute of Technology University Vellore- 632014, Tamil Nadu India
- Drug metabolism and pharmacokineticsEurofins Advinus Limited, # 21 and 22, Peenya II Phase, Peenya Bengaluru- 560058, Karnataka India
| | - Priyankar Paira
- Department of ChemistrySchool of Advanced SciencesVellore Institute of Technology University Vellore- 632014, Tamil Nadu India
| |
Collapse
|
20
|
Kamal R, Kumar R, Kumar V, Kumar V, Bansal KK, Sharma PC. Synthesis, Anthelmintic and Antimicrobial Evaluation of New 2‐Arylidene‐1‐(4‐methyl‐6‐phenylpyrimidin‐2‐yl)hydrazines. ChemistrySelect 2019. [DOI: 10.1002/slct.201802822] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Raj Kamal
- Department of ChemistryKurukshetra University, Kurukshetra, Haryana India)- 136119
| | - Ravinder Kumar
- Department of ChemistryKurukshetra University, Kurukshetra, Haryana India)- 136119
| | - Vipan Kumar
- Department of ChemistryKurukshetra University, Kurukshetra, Haryana India)- 136119
| | - Vikas Kumar
- Department of BiotechnologyMaharishi Markandeshwar (Deemed to be University), Mullana, Haryana India)- 133207
| | - Kushal K. Bansal
- Department of Pharmaceutical SciencesKurukshetra University, Kurukshetra, Haryana India)- 136119
| | - Prabodh C. Sharma
- Department of Pharmaceutical SciencesKurukshetra University, Kurukshetra, Haryana India)- 136119
| |
Collapse
|
21
|
Wang Q, Wan J, Zhang W, Hao S. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells. Leuk Lymphoma 2019; 60:2170-2180. [PMID: 30626241 DOI: 10.1080/10428194.2018.1563694] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Aberrant over-expression of BCL-2 family proteins (BCL-2, BCL-xL, MCL-1) are associated with hematological malignancies. Antagonists of BCL-2 family proteins include BCL-2-selective inhibitor ABT-199, MCL-1-selective inhibitor A-1210477, BCL-xL-selective inhibitor A-1155463. In this study, we evaluated their potential inhibitory effectiveness. Our data showed that OCI-AML3 cells and U937 cells were resistant to BCL-2-selective inhibitor ABT-199 in vitro and in vivo, however, while OCI-AML3 cells were sensitive to MCL-1-selective inhibitor A-1210477 in vitro and in vivo, indicating that A-1210477 could counteract the resistance of AML cells to ABT-199 as a single agent in MCL-1-dependent AML cells. U-937 cell line and mouse model were resistant to A-1210477 or ABT-199, and expressed high level of BCL-xL, indicating that BCL-xL might play an important role in the resistance of A-1210477 or ABT-199. Besides, this study also showed that ABT-199 could synergize with A-1210477 in vitro or in vivo.
Collapse
Affiliation(s)
- Qing Wang
- Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , China
| | - Jiangbo Wan
- Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , China
| | - Wenhao Zhang
- Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , China
| | - Siguo Hao
- Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , China
| |
Collapse
|
22
|
Ivanov SM, Huber RG, Alibay I, Warwicker J, Bond PJ. Energetic Fingerprinting of Ligand Binding to Paralogous Proteins: The Case of the Apoptotic Pathway. J Chem Inf Model 2018; 59:245-261. [DOI: 10.1021/acs.jcim.8b00765] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Stefan M. Ivanov
- Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester, 131 Princess Street, Manchester M1 7DN, U.K
- Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Matrix 07-01, 30 Biopolis Street, Singapore 138671, Singapore
| | - Roland G. Huber
- Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Matrix 07-01, 30 Biopolis Street, Singapore 138671, Singapore
| | - Irfan Alibay
- Division of Pharmacy and Optometry, School of Health Sciences, The University of Manchester, Oxford Road, Manchester M13 9PT, U.K
| | - Jim Warwicker
- Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester, 131 Princess Street, Manchester M1 7DN, U.K
| | - Peter J. Bond
- Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Matrix 07-01, 30 Biopolis Street, Singapore 138671, Singapore
- Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore 117543, Singapore
| |
Collapse
|
23
|
Gupta P, Gutcaits A. Development and Validation of a Robust QSAR Model for Benzothiazole Hydrazone Derivatives as Bcl-XL Inhibitors. LETT DRUG DES DISCOV 2018. [DOI: 10.2174/1570180815666180502093039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Background:
B-cell Lymphoma Extra Large (Bcl-XL) belongs to B-cell Lymphoma two
(Bcl-2) family. Due to its over-expression and anti-apoptotic role in many cancers, it has been proven
to be a more biologically relevant therapeutic target in anti-cancer therapy. In this study, a Quantitative
Structure Activity Relationship (QSAR) modeling was performed to establish the link between
structural properties and inhibitory potency of benzothiazole hydrazone derivatives against Bcl-XL.
Methods:
The 53 benzothiazole hydrazone derivatives have been used for model development using
genetic algorithm and multiple linear regression methods. The data set is divided into training and
test set using Kennard-Stone based algorithm. The best QSAR model has been selected with statistically
significant r2 = 0.931, F-test =55.488 RMSE = 0.441 and Q2 0.900.
Results:
The model has been tested successfully for external validation (r2
pred = 0.752), as well as
different criteria for acceptable model predictability. Furthermore, analysis of the applicability domain
has been carried out to evaluate the prediction reliability of external set molecules. The developed
QSAR model has revealed that nThiazoles, nROH, EEig13d, WA, BEHv6, HATS6m,
RDF035u and IC4 descriptors are important physico-chemical properties for determining the inhibitory
activity of these molecules.
Conclusion:
The developed QSAR model is stable for this chemical series, indicating that test set
molecules represent the training dataset. The model is statistically reliable with good predictability.
The obtained descriptors reflect important structural features required for activity against Bcl-XL.
These properties are designated by topology, shape, size, geometry, substitution information of the
molecules (nThiazoles and nROH) and electronic properties. In a nutshell, these characteristics can
be successfully utilized for designing and screening of novel inhibitors.
Collapse
Affiliation(s)
- Pawan Gupta
- CNS Active Compound Laboratory, Latvian Institute of Organic Synthesis, Riga, LV1006, Latvia
| | - Aleksandrs Gutcaits
- CNS Active Compound Laboratory, Latvian Institute of Organic Synthesis, Riga, LV1006, Latvia
| |
Collapse
|
24
|
Osmaniye D, Levent S, Karaduman AB, Ilgın S, Özkay Y, Kaplancıklı ZA. Synthesis of New Benzothiazole Acylhydrazones as Anticancer Agents. Molecules 2018; 23:molecules23051054. [PMID: 29724002 PMCID: PMC6102592 DOI: 10.3390/molecules23051054] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Revised: 04/27/2018] [Accepted: 04/27/2018] [Indexed: 12/05/2022] Open
Abstract
During the last five decades, a large number of BT (Benzothiazole) derivatives formed one of the eligible structures in medicinal chemistry as anticancer agents. Most of the studies reveal that various substitutions at specific positions on BT scaffold modulate the antitumor property. The potential of BTs encouraged us to synthesize a number of new 2-((5-substitutedbenzothiazol-2-yl)thio)-N’-(2-(4-(substitutedphenyl)ethylidene)acetohydrazide derivatives and investigate their probable anticancer activity. 4-Substitued benzaldehyde derivatives (1a–1e) were afforded by the reaction of appropriate secondary amine and 4-fluorobenzaldehyde in DMF. Equimolar quantitates of 5-substitutedbenzothiazole-2-thiol, ethyl chloroacetate and K2CO3 were refluxed in acetone to obtain 2-((5-substitutedbenzothiazol-2-yl)thio)acetate derivatives (2a,2b), which reacted with excess of hydrazine hydrate to get 2-((5-substitutebenzothiazol-2-yl)thio)acetohydrazides (3a,3b). In the last step, 2-((5-substitutedbenzothiazol-2-yl)thio)-N’-(4-substitutedbenzylidene)acetohydrazide derivatives (4a–4j) were synthesized by the reaction of 1a–1e and 3a–3b in EtOH. The anticancer activity of target compounds was evaluated in three steps. First, an MTT test (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was performed to observe cytotoxic activity of the compounds against carcinogenic C6 (Rat brain glioma cell line), A549 (Human lung adenocarcinoma epithelial cell line), MCF-7 (Human breast adenocarcinoma cell line), and HT-29 (Human colorectal adenocarcinoma cell line) cancer cell lines. Healthy NIH3T3 (Mouse embryo fibroblast cell line) cells were also subjected to MTT assay to determine selectivity of the compounds towards carcinogenic cell lines. Secondly, inhibitory effects of selected compounds 4d, 4e, and 4h on DNA synthesis of C6 cells were investigated. Finally, flow cytometric analysis were performed to identify the death pathway of the carcinogenic cells.
Collapse
Affiliation(s)
- Derya Osmaniye
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
- Doping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
| | - Serkan Levent
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
- Doping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
| | - Abdullah Burak Karaduman
- Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Anadolu Universty, 26470 Eskişehir, Turkey.
| | - Sinem Ilgın
- Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Anadolu Universty, 26470 Eskişehir, Turkey.
| | - Yusuf Özkay
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
- Doping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
| | - Zafer Asım Kaplancıklı
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey.
| |
Collapse
|
25
|
Synthesis, cytotoxicity and anti-metastatic properties of new pyridyl-thiazole arene ruthenium(II) complexes. Appl Organomet Chem 2018. [DOI: 10.1002/aoc.4311] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
26
|
3,5-[5-Arylisoxazol-3-yl(4,5-dichloroisothiazol-3-yl)]-substituted 1,2,4- and 1,3,4-oxadiazoles: synthesis, palladium complexes, and catalysis of Suzuki reactions in aqueous media. Chem Heterocycl Compd (N Y) 2018. [DOI: 10.1007/s10593-018-2216-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Shukla S, Saxena S, Singh BK, Kakkar P. BH3-only protein BIM: An emerging target in chemotherapy. Eur J Cell Biol 2017; 96:728-738. [PMID: 29100606 DOI: 10.1016/j.ejcb.2017.09.002] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 09/01/2017] [Accepted: 09/19/2017] [Indexed: 12/19/2022] Open
Abstract
BH3-only proteins constitute major proportion of pro-apoptotic members of B-cell lymphoma 2 (Bcl-2) family of apoptotic regulatory proteins and participate in embryonic development, tissue homeostasis and immunity. Absence of BH3-only proteins contributes to autoimmune disorders and tumorigenesis. Bim (Bcl-2 Interacting Mediator of cell death), most important member of BH3-only proteins, shares a BH3-only domain (9-16 aa) among 4 domains (BH1-BH4) of Bcl-2 family proteins and highly pro-apoptotic in nature. Bim initiates the intrinsic apoptotic pathway under both physiological and patho-physiological conditions. Reduction in Bim expression was found to be associated with tumor promotion and autoimmunity, while overexpression inhibited tumor growth and drug resistance as cancer cells suppress Bim expression and stability. Apart from its role in normal homeostasis, Bim has emerged as a central player in regulation of tumorigenesis, therefore gaining attention as a plausible target for chemotherapy. Regulation of Bim expression and stability is complicated and regulated at multiple levels viz. transcriptional, post-transcriptional, post-translational (preferably by phosphorylation and ubiquitination), epigenetic (by promoter acetylation or methylation) including miRNAs. Furthermore, control over Bim expression and stability may be exploited to enhance chemotherapeutic efficacy, overcome drug resistance and select anticancer drug regimen as various chemotherapeutic agents exploit Bim as an executioner of cell death. Owing to its potent anti-tumorigenic activity many BH3 mimetics e.g. ABT-737, ABT-263, obatoclax, AT-101and A-1210477 have been developed and entered in clinical trials. It is more likely that in near future strategies commanding Bim expression and stability ultimately lead to Bim based therapeutic regimen for cancer treatment.
Collapse
Affiliation(s)
- Shatrunajay Shukla
- Herbal Research Laboratory, Food Drug & Chemical Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan 31, Post Box No. 80, Mahatma Gandhi Marg, Lucknow 226001, India
| | - Sugandh Saxena
- Herbal Research Laboratory, Food Drug & Chemical Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan 31, Post Box No. 80, Mahatma Gandhi Marg, Lucknow 226001, India; Academy of Scientific and Innovative Research, CSIR-IITR, Lucknow campus, India
| | - Brijesh Kumar Singh
- Laboratory of Hormonal Regulation, Duke-NUS Graduate Medical School, No 8 College Road, 169857, Singapore
| | - Poonam Kakkar
- Herbal Research Laboratory, Food Drug & Chemical Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan 31, Post Box No. 80, Mahatma Gandhi Marg, Lucknow 226001, India; Academy of Scientific and Innovative Research, CSIR-IITR, Lucknow campus, India.
| |
Collapse
|
28
|
Geiger L, Nieger M, Bräse S. Suzuki-Miyaura Cross-Coupling Reactions of Tetrahydroxanthones and 4-Chromanone Lactones to Heteromeric Biaryls. Adv Synth Catal 2017. [DOI: 10.1002/adsc.201700497] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Larissa Geiger
- Institute of Organic Chemistry; Karlsruhe Institute of Technology (KIT); Fritz-Haber-Weg 6 76131 Karlsruhe Germany
| | - Martin Nieger
- Department of Chemistry; University of Helsinki; P. O. Box 55 00014 University of Helsinki Finland
| | - Stefan Bräse
- Institute of Organic Chemistry; Karlsruhe Institute of Technology (KIT); Fritz-Haber-Weg 6 76131 Karlsruhe Germany
- Institute of Toxicology and Genetics; Karlsruhe Institute of Technology (KIT); Hermann-von-Helmholtz-Platz 1 76344 Eggenstein-Leopoldshafen Germany
| |
Collapse
|
29
|
Marimuthu P, Balasubramanian PK, Singaravelu K. Deciphering the crucial molecular properties of a series of Benzothiazole Hydrazone inhibitors that targets anti-apoptotic Bcl-xL protein. J Biomol Struct Dyn 2017; 36:2654-2667. [DOI: 10.1080/07391102.2017.1365771] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Parthiban Marimuthu
- Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Tykistökatu 6A, Turku FI-20520, Finland
- Department of Biology, Albany State University, 504 College Drive, Albany, GA, USA
| | - Pavithra K. Balasubramanian
- Department of Biomedical Sciences, College of Medicine, Chosun University, 375 Seosuk-dong, Dong-gu, Gwangju 61452, Republic of Korea
| | | |
Collapse
|
30
|
Chhabra M, Babu LT, Mondal A, Sun H, Paira P. Amberlite IRA 402(OH) Mediated Green Synthesis of Novel Benzothiazole–quinoline Conjugates as Cancer Theranostics. ChemistrySelect 2017. [DOI: 10.1002/slct.201700066] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Mohit Chhabra
- Department of ChemistrySchool of Advanced SciencesVellore Institute of Technology University Vellore-632014, Tamil Nadu India
- Department of Biology and ChemistryCity University of Hong Kong 83 Tat Chee Avenue, Kowloon Hong Kong P. R. China
| | - Lavanya Thilak Babu
- Department of ChemistrySchool of Advanced SciencesVellore Institute of Technology University Vellore-632014, Tamil Nadu India
| | - Ashaparna Mondal
- Department of ChemistrySchool of Advanced SciencesVellore Institute of Technology University Vellore-632014, Tamil Nadu India
| | - Hongyan Sun
- Department of Biology and ChemistryCity University of Hong Kong 83 Tat Chee Avenue, Kowloon Hong Kong P. R. China
| | - Priyankar Paira
- Department of ChemistrySchool of Advanced SciencesVellore Institute of Technology University Vellore-632014, Tamil Nadu India
| |
Collapse
|
31
|
Kanakaveti V, Sakthivel R, Rayala SK, Gromiha MM. Importance of functional groups in predicting the activity of small molecule inhibitors for Bcl-2 and Bcl-xL. Chem Biol Drug Des 2017; 90:308-316. [DOI: 10.1111/cbdd.12952] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Revised: 11/21/2016] [Accepted: 11/30/2016] [Indexed: 01/22/2023]
Affiliation(s)
- Vishnupriya Kanakaveti
- Protein Bioinformatics Lab; Department of Biotechnology; Bhupat and Jyoti Mehta School of Biosciences; Indian Institute of Technology Madras; Chennai Tamil Nadu India
| | - Ramasamy Sakthivel
- Protein Bioinformatics Lab; Department of Biotechnology; Bhupat and Jyoti Mehta School of Biosciences; Indian Institute of Technology Madras; Chennai Tamil Nadu India
| | - S. K. Rayala
- Molecular Oncology Lab; Department of Biotechnology; Bhupat and Jyoti Mehta School of Biosciences; Indian Institute of Technology Madras; Chennai Tamil Nadu India
| | - M. Michael Gromiha
- Protein Bioinformatics Lab; Department of Biotechnology; Bhupat and Jyoti Mehta School of Biosciences; Indian Institute of Technology Madras; Chennai Tamil Nadu India
| |
Collapse
|
32
|
Wang Z, Xu W, Song T, Guo Z, Liu L, Fan Y, Wang A, Zhang Z. Fragment-Based Design, Synthesis, and Biological Evaluation of 1-Substituted-indole-2-carboxylic Acids as Selective Mcl-1 Inhibitors. Arch Pharm (Weinheim) 2016; 350. [PMID: 27911011 DOI: 10.1002/ardp.201600251] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 11/08/2016] [Accepted: 11/09/2016] [Indexed: 11/10/2022]
Abstract
Based on a known selective Mcl-1 inhibitor, 6-chloro-3-(3-(4-chloro-3,5-dimethylphenoxy)propyl)-1H-indole-2-carboxylic acid, we applied a fragment-based approach to obtain new molecules that extended into the p1 pocket of the BH3 groove and then exhibited binding selectivity for the Mcl-1 over the Bcl-2 protein. After we deconstructed the 1H-indole-2-carboxylic acid from the parental molecule, a benzenesulfonyl was substituted at the 1-position to adopt a geometry preferred for accessing the p1 pocket according to the binding mode of the parental molecule identified by X-ray crystallography. A linear relationship between the free energy of ligand binding (ΔG) and the count of non-hydrogen heavy atoms (HAC) was maintained during the molecular growing to occupy the p1 pocket. Finally, we not only obtained compound 12 with a 7.5-fold selectivity to Mcl-1 (Ki = 0.48 µM by fluorescence polarization) over Bcl-2 (Ki = 3.6 µM), but also provided evidence that additional occupation of the p1 pocket is more favorable for Mcl-1 than for Bcl-2 binding, and contributes more to Mcl-1 inhibition than occupation of the p2 pocket. Compound 12 exhibited a selective killing ability on Mcl-1-dependent cancer cells.
Collapse
Affiliation(s)
- Ziqian Wang
- State Key Laboratory of Fine Chemicals, School of Chemistry, Dalian University of Technology, Dalian, People's Republic of China
| | - Wenjie Xu
- State Key Laboratory of Fine Chemicals, School of Chemistry, Dalian University of Technology, Dalian, People's Republic of China
| | - Ting Song
- School of Life Science and Technology, Dalian University of Technology, Dalian, People's Republic of China
| | - Zongwei Guo
- School of Life Science and Technology, Dalian University of Technology, Dalian, People's Republic of China
| | - Lu Liu
- State Key Laboratory of Fine Chemicals, School of Chemistry, Dalian University of Technology, Dalian, People's Republic of China
| | - Yudan Fan
- School of Life Science and Technology, Dalian University of Technology, Dalian, People's Republic of China
| | - Anhui Wang
- State Key Laboratory of Fine Chemicals, School of Chemistry, Dalian University of Technology, Dalian, People's Republic of China
| | - Zhichao Zhang
- State Key Laboratory of Fine Chemicals, School of Chemistry, Dalian University of Technology, Dalian, People's Republic of China
| |
Collapse
|
33
|
Hennessy EJ. Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity. Bioorg Med Chem Lett 2016; 26:2105-14. [DOI: 10.1016/j.bmcl.2016.03.032] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Revised: 03/08/2016] [Accepted: 03/09/2016] [Indexed: 10/22/2022]
|
34
|
Lim Z, Duggan PJ, Wan SS, Lessene G, Meyer AG, Tuck KL. Exploiting the Biginelli reaction: nitrogen-rich pyrimidine-based tercyclic α-helix mimetics. Tetrahedron 2016. [DOI: 10.1016/j.tet.2015.12.044] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
35
|
Bumagin NA, Zelenkovskii VM, Kletskov AV, Petkevich SK, Dikusar EA, Potkin VI. Functionally substituted isoxazoles and isothiazoles: Synthesis, palladium(II) complexes and their catalytic activity. RUSS J GEN CHEM+ 2016. [DOI: 10.1134/s1070363216010138] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
36
|
Pany SPP, Bommisetti P, Diveshkumar KV, Pradeepkumar PI. Benzothiazole hydrazones of furylbenzamides preferentially stabilize c-MYC and c-KIT1 promoter G-quadruplex DNAs. Org Biomol Chem 2016; 14:5779-93. [DOI: 10.1039/c6ob00138f] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The stabilization of G-quadruplex DNA structures by using small molecule ligands having simple structural scaffolds has the potential to be harnessed for developing next generation anticancer agents.
Collapse
Affiliation(s)
| | - Praneeth Bommisetti
- Department of Chemistry
- Indian Institute of Technology Bombay
- Mumbai-400076
- India
| | - K. V. Diveshkumar
- Department of Chemistry
- Indian Institute of Technology Bombay
- Mumbai-400076
- India
| | - P. I. Pradeepkumar
- Department of Chemistry
- Indian Institute of Technology Bombay
- Mumbai-400076
- India
| |
Collapse
|
37
|
Tassini S, Castagnolo D, Scalacci N, Kissova M, Armijos-Rivera JI, Giagnorio F, Maga G, Costantino G, Crespan E, Radi M. A multicomponent pharmacophore fragment-decoration approach to identify selective LRRK2-targeting probes. MEDCHEMCOMM 2016. [DOI: 10.1039/c5md00462d] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Herein we report the development of a new versatile chemical tool for the rapid identification of LRRK2-targeting probes as potential anti-Parkinson's agents.
Collapse
Affiliation(s)
- Sabrina Tassini
- P4T Group, Dipartimento di Farmacia
- Università degli Studi di Parma
- 43124 Parma
- Italy
| | - Daniele Castagnolo
- Institute of Pharmaceutical Science
- King's College London
- SE1 9NH London
- UK
- Northumbria University Newcastle
| | - Nicolò Scalacci
- Institute of Pharmaceutical Science
- King's College London
- SE1 9NH London
- UK
- Northumbria University Newcastle
| | | | | | - Federica Giagnorio
- P4T Group, Dipartimento di Farmacia
- Università degli Studi di Parma
- 43124 Parma
- Italy
- Northumbria University Newcastle
| | | | - Gabriele Costantino
- P4T Group, Dipartimento di Farmacia
- Università degli Studi di Parma
- 43124 Parma
- Italy
| | | | - Marco Radi
- P4T Group, Dipartimento di Farmacia
- Università degli Studi di Parma
- 43124 Parma
- Italy
| |
Collapse
|
38
|
Jalali-Yazdi F, Takahashi TT, Roberts RW. General, Label-Free Method for Determining K(d) and Ligand Concentration Simultaneously. Anal Chem 2015; 87:11755-62. [PMID: 26485531 DOI: 10.1021/acs.analchem.5b03069] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Some of the most commonly used affinity reagents (e.g., antibodies) are often developed and used in conditions where their input concentrations ([L]0) and affinities (K(d)) are not known. Here, we have developed a general approach to determine both [L]0 and K(d) values simultaneously for affinity reagents (small molecules, proteins, and antibodies). To do this, we perform quantitative equilibrium exclusion immunoassays with two different concentrations of target and fit the data simultaneously to determine K(d) and [L]0. The results give accurate and reproducible measures of both values compared to established methods. By performing detailed error analysis, we demonstrate that our fitting gives unique solutions and indicates where K(d) and [L]0 measures are reliable. Furthermore, we found that a divalent model of antibody binding gives accurate K(d) and [L]0 values in both the forward (antibody immobilized) and the reverse (target immobilized) assays-addressing the long-term problem of obtaining quantitative data from reverse assays.
Collapse
Affiliation(s)
- Farzad Jalali-Yazdi
- Mork Family Department of Chemical Engineering and Materials Science, ‡Department of Chemistry, §Department of Molecular Computational Biology, and ∥USC Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, California 90089-2905, United States
| | - Terry T Takahashi
- Mork Family Department of Chemical Engineering and Materials Science, ‡Department of Chemistry, §Department of Molecular Computational Biology, and ∥USC Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, California 90089-2905, United States
| | - Richard W Roberts
- Mork Family Department of Chemical Engineering and Materials Science, ‡Department of Chemistry, §Department of Molecular Computational Biology, and ∥USC Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, California 90089-2905, United States
| |
Collapse
|
39
|
Grozav A, Balacescu O, Balacescu L, Cheminel T, Berindan-Neagoe I, Therrien B. Synthesis, Anticancer Activity, and Genome Profiling of Thiazolo Arene Ruthenium Complexes. J Med Chem 2015; 58:8475-90. [PMID: 26488797 DOI: 10.1021/acs.jmedchem.5b00855] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Sixteen hydrazinyl-thiazolo arene ruthenium complexes of the general formula [(η(6)-p-cymene)Ru(N,N'-hydrazinyl-thiazolo)Cl]Cl were synthesized. All complexes were tested in vitro for their antiproliferative activity on three tumor cell lines (HeLa, A2780, and A2780cisR) and on a noncancerous cell line (HFL-1). A superior cytotoxic activity of the ruthenium complexes as compared to cisplatin and oxaliplatin, on both cisplatin-sensitive and cisplatin resistant ovarian cancer cells, was observed. In addition, the biological activity of two selected derivatives was evaluated using microarray gene expression assay and ingenuity pathway analysis. p53 signaling was identified as an important pathway modulated by both arene ruthenium compounds. New activated molecules such as FAS, ZMAT3, PRMT2, BBC3/PUMA, and PDCD4, whose overexpressions are correlated with overcoming resistance to cisplatin therapy, were also identified as potential targets. Moreover, the arene ruthenium complexes can be used in association with cisplatin to prevent cisplatin resistance development and synergistically to induce cell death in ovarian cancer cells.
Collapse
Affiliation(s)
- Adriana Grozav
- Faculty of Pharmacy, "Iuliu Hatieganu" University of Medicine and Pharmacy , Victor Babes Str. 41, RO-400012 Cluj-Napoca, Romania
| | - Ovidiu Balacescu
- Department of Functional Genomics, Proteomics and Experimental Pathology, The Oncology Institute "Prof Dr. Ion Chiricuta" , 34-36 Republicii Str, RO-400015, Cluj-Napoca, Romania
| | - Loredana Balacescu
- Department of Functional Genomics, Proteomics and Experimental Pathology, The Oncology Institute "Prof Dr. Ion Chiricuta" , 34-36 Republicii Str, RO-400015, Cluj-Napoca, Romania
| | - Thomas Cheminel
- Institut de Chimie, Université de Neuchâtel , 51 Avenue de Bellevaux, CH-2000 Neuchâtel, Switzerland
| | - Ioana Berindan-Neagoe
- Department of Functional Genomics, Proteomics and Experimental Pathology, The Oncology Institute "Prof Dr. Ion Chiricuta" , 34-36 Republicii Str, RO-400015, Cluj-Napoca, Romania.,Research Center of Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu″ University of Medicine and Pharmacy , 23 Marinescu Str, RO-400337 Cluj-Napoca, Romania
| | - Bruno Therrien
- Institut de Chimie, Université de Neuchâtel , 51 Avenue de Bellevaux, CH-2000 Neuchâtel, Switzerland
| |
Collapse
|
40
|
Yu X, Shi L, Ke S. Acylhydrazone derivatives as potential anticancer agents: Synthesis, bio-evaluation and mechanism of action. Bioorg Med Chem Lett 2015; 25:5772-6. [PMID: 26546214 DOI: 10.1016/j.bmcl.2015.10.069] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Revised: 09/18/2015] [Accepted: 10/22/2015] [Indexed: 01/28/2023]
Abstract
A series of novel acylhydrazone derivatives were designed, synthesized and evaluated for their potential cytotoxic effects against human cancer cell lines. The preliminary results indicated that some of the obtained compounds (such as 8b, 13c) exhibited good to moderate cytotoxic activities against human HepG2, Huh-7, and BCG-823 cell lines. Especially, compounds 8c and 8e presented obviously selective cytotoxic activities against Huh-7 in vitro (8c, IC50=7.74±2.18μg/mL; 8e, IC50=4.46±1.05μg/mL) compared to 5-FU (IC50=10.41±3.41μg/mL). The highly potential compounds to induce apoptosis in HepG2 cells were analyzed by flow cytometry, and the apoptotic effects of compounds 8b and 13c were further evaluated using Annexin V-FITC/propidium iodide dual staining assay.
Collapse
Affiliation(s)
- Xifang Yu
- Huangshi Central Hospital, Hubei Polytechnic University, Huangshi 435000, People's Republic of China
| | - Liqiao Shi
- National Biopesticide Engineering Research Center, Hubei Academy of Agricultural Sciences, Wuhan 430064, People's Republic of China
| | - Shaoyong Ke
- National Biopesticide Engineering Research Center, Hubei Academy of Agricultural Sciences, Wuhan 430064, People's Republic of China.
| |
Collapse
|
41
|
Highlights from SelectBio 2015: Academic Drug Discovery Conference, Cambridge, UK, 19-20 May 2015. Future Med Chem 2015; 7:1839-42. [PMID: 26420379 DOI: 10.4155/fmc.15.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The SelectBio 2015: Academic Drug Discovery Conference was held in Cambridge, UK, on 19-20 May 2015. Building on the success of academic drug discovery events in the USA, this conference aimed to showcase the exciting new research emerging from academic drug discovery and to help bridge the gap between basic research and commercial application. At the event the authors heard from a number of speakers on a broad array of topics, from partnering models for academia and industry to novel drug discovery approaches across various therapeutic areas, with a few talks, such as those by Susanne Muller-Knapp (Structure Genomics Consortium, Oxford University, Oxford, UK) and Julian Blagg (Institute of Cancer Research, UK), covering both remits, by highlighting a number of such partnerships and then delving into some case studies. The conference concluded with a heated debate on whether phenotypic discovery should be favored over targeted discovery in academia and pharma, in a panel discussion chaired by Roland Wolkowicz (San Diego State University, USA).
Collapse
|
42
|
Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. Oncogene 2015; 35:1877-87. [PMID: 26257067 DOI: 10.1038/onc.2015.287] [Citation(s) in RCA: 100] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Revised: 05/26/2015] [Accepted: 06/08/2015] [Indexed: 01/07/2023]
Abstract
The last three decades have seen significant progress in our understanding of the role of the pro-survival protein BCL-2 and its family members in apoptosis and cancer. BCL-2 and other pro-survival family members including Mcl-1 and BCL-XL have been shown to have a key role in keeping pro-apoptotic 'effector' proteins BAK and BAX in check. They also neutralize a group of 'sensor' proteins (such as BIM), which are triggered by cytotoxic stimuli such as chemotherapy. BCL-2 proteins therefore have a central role as guardians against apoptosis, helping cancer cells to evade cell death. More recently, an increasing number of BH3 mimetics, which bind and neutralize BCL-2 and/or its pro-survival relatives, have been developed. The utility of targeting BCL-2 in hematological malignancies has become evident in early-phase studies, with remarkable clinical responses seen in heavily pretreated patients. As BCL-2 is overexpressed in ~75% of breast cancer, there has been growing interest in determining whether this new class of drug could show similar promise in breast cancer. This review summarizes our current understanding of the role of BCL-2 and its family members in mammary gland development and breast cancer, recent progress in the development of new BH3 mimetics as well as their potential for targeting estrogen receptor-positive breast cancer.
Collapse
|
43
|
Baell JB. Screening-based translation of public research encounters painful problems. ACS Med Chem Lett 2015; 6:229-34. [PMID: 25941544 DOI: 10.1021/acsmedchemlett.5b00032] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Indexed: 12/22/2022] Open
Abstract
Whether identified through high throughput screening or in silico screening, and whether target-based or phenotypic, sets of hits will contain chemical con artists. Such pan-assay interference compounds (PAINS) and other subversive compounds continue to pollute the scientific literature. There are several angles of attack to aid identification of such nonprogressable molecules. One of these rules above all, and this is a demonstration of genuine structure-activity relationships. Recognition of this, which will require a greater effort in medicinal chemistry, will be of general benefit.
Collapse
Affiliation(s)
- Jonathan B. Baell
- Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, Victoria 3052, Australia
| |
Collapse
|
44
|
Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, Nimmer P, Jin S, Smith M, Xiao Y, Kovar P, Tanaka A, Bruncko M, Sheppard GS, Wang L, Gierke S, Kategaya L, Anderson DJ, Wong C, Eastham-Anderson J, Ludlam MJC, Sampath D, Fairbrother WJ, Wertz I, Rosenberg SH, Tse C, Elmore SW, Souers AJ. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 2015; 6:e1590. [PMID: 25590800 PMCID: PMC4669759 DOI: 10.1038/cddis.2014.561] [Citation(s) in RCA: 355] [Impact Index Per Article: 39.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Revised: 11/24/2014] [Accepted: 11/27/2014] [Indexed: 11/09/2022]
Abstract
The anti-apoptotic protein MCL-1 is a key regulator of cancer cell survival and a known resistance factor for small-molecule BCL-2 family inhibitors such as ABT-263 (navitoclax), making it an attractive therapeutic target. However, directly inhibiting this target requires the disruption of high-affinity protein-protein interactions, and therefore designing small molecules potent enough to inhibit MCL-1 in cells has proven extremely challenging. Here, we describe a series of indole-2-carboxylic acids, exemplified by the compound A-1210477, that bind to MCL-1 selectively and with sufficient affinity to disrupt MCL-1-BIM complexes in living cells. A-1210477 induces the hallmarks of intrinsic apoptosis and demonstrates single agent killing of multiple myeloma and non-small cell lung cancer cell lines demonstrated to be MCL-1 dependent by BH3 profiling or siRNA rescue experiments. As predicted, A-1210477 synergizes with the BCL-2/BCL-XL inhibitor navitoclax to kill a variety of cancer cell lines. This work represents the first description of small-molecule MCL-1 inhibitors with sufficient potency to induce clear on-target cellular activity. It also demonstrates the utility of these molecules as chemical tools for dissecting the basic biology of MCL-1 and the promise of small-molecule MCL-1 inhibitors as potential therapeutics for the treatment of cancer.
Collapse
Affiliation(s)
- J D Leverson
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - H Zhang
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - J Chen
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - S K Tahir
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - D C Phillips
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - J Xue
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - P Nimmer
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - S Jin
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - M Smith
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - Y Xiao
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - P Kovar
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - A Tanaka
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - M Bruncko
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - G S Sheppard
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - L Wang
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - S Gierke
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - L Kategaya
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - D J Anderson
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - C Wong
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | | | - M J C Ludlam
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - D Sampath
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - W J Fairbrother
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - I Wertz
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - S H Rosenberg
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - C Tse
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - S W Elmore
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| | - A J Souers
- Oncology Development, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA
| |
Collapse
|
45
|
Keri RS, Patil MR, Patil SA, Budagumpi S. A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. Eur J Med Chem 2014; 89:207-51. [PMID: 25462241 DOI: 10.1016/j.ejmech.2014.10.059] [Citation(s) in RCA: 298] [Impact Index Per Article: 29.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Revised: 10/19/2014] [Accepted: 10/20/2014] [Indexed: 02/08/2023]
Abstract
Benzothiazole (BTA) and its derivatives are the most important heterocyclic compounds, which are common and integral feature of a variety of natural products and pharmaceutical agents. BTA shows a variety of pharmacological properties, and its analogs offer a high degree of structural diversity that has proven useful for the search of new therapeutic agents. The broad spectrum of pharmacological activity in individual BTA derivative indicates that, this series of compounds is of an undoubted interest. The related research and developments in BTA-based medicinal chemistry have become a rapidly developing and increasingly active topic. Particularly, numerous BTA-based compounds as clinical drugs have been extensively used in practice to treat various types of diseases with high therapeutic potency. This work systematically gives a comprehensive review in current developments of BTA-based compounds in the whole range of medicinal chemistry as anticancer, antibacterial, antifungal, antiinflammatory, analgesic, anti-HIV, antioxidant, anticonvulsant, antitubercular, antidiabetic, antileishmanial, antihistaminic, antimalarial and other medicinal agents. It is believed that, this review article is helpful for new thoughts in the quest for rational designs of more active and less toxic BTA-based drugs, as well as more effective diagnostic agents and pathologic probes.
Collapse
Affiliation(s)
- Rangappa S Keri
- Centre for Nano and Material Sciences, Jain University, Jain Global Campus, Bangalore 562112, Karnataka, India.
| | - Mahadeo R Patil
- Centre for Nano and Material Sciences, Jain University, Jain Global Campus, Bangalore 562112, Karnataka, India
| | - Siddappa A Patil
- Centre for Nano and Material Sciences, Jain University, Jain Global Campus, Bangalore 562112, Karnataka, India
| | - Srinivasa Budagumpi
- Centre for Nano and Material Sciences, Jain University, Jain Global Campus, Bangalore 562112, Karnataka, India
| |
Collapse
|
46
|
Potkin VI, Bumagin NA, Zelenkovskii VM, Petkevich SK, Livantsov MV, Golantsov NE. 5-(Naphth-1-yl)- and 5-[(1,1′-biphenyl)-4-yl]isoxazole-3-carbaldehyde oximes: Synthesis, complexes with palladium, and application in catalysis. RUSS J GEN CHEM+ 2014. [DOI: 10.1134/s1070363214090242] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
47
|
Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM, Czabotar PE, Deshayes K, Fairbrother WJ, Flygare JA, Hymowitz SG, Jin S, Judge RA, Koehler MFT, Kovar PJ, Lessene G, Mitten MJ, Ndubaku CO, Nimmer P, Purkey HE, Oleksijew A, Phillips DC, Sleebs BE, Smith BJ, Smith ML, Tahir SK, Watson KG, Xiao Y, Xue J, Zhang H, Zobel K, Rosenberg SH, Tse C, Leverson JD, Elmore SW, Souers AJ. Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. ACS Med Chem Lett 2014; 5:1088-93. [PMID: 25313317 DOI: 10.1021/ml5001867] [Citation(s) in RCA: 215] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2014] [Accepted: 08/26/2014] [Indexed: 11/30/2022] Open
Abstract
A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based design. This compound is substantially more potent against BCL-XL-dependent cell lines relative to our recently reported inhibitor, WEHI-539, while possessing none of its inherent pharmaceutical liabilities. A-1155463 caused a mechanism-based and reversible thrombocytopenia in mice and inhibited H146 small cell lung cancer xenograft tumor growth in vivo following multiple doses. A-1155463 thus represents an excellent tool molecule for studying BCL-XL biology as well as a productive lead structure for further optimization.
Collapse
Affiliation(s)
- Zhi-Fu Tao
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Lisa Hasvold
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Le Wang
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Xilu Wang
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Andrew M. Petros
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Chang H. Park
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Erwin R. Boghaert
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Nathaniel D. Catron
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Jun Chen
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Peter M. Colman
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department
of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Peter E. Czabotar
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department
of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Kurt Deshayes
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 United States
| | | | - John A. Flygare
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 United States
| | - Sarah G. Hymowitz
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 United States
| | - Sha Jin
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Russell A. Judge
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | | | - Peter J. Kovar
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Guillaume Lessene
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department
of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia
- Department
of Pharmacology and Therapeutics, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Michael J. Mitten
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Chudi O. Ndubaku
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 United States
| | - Paul Nimmer
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Hans E. Purkey
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 United States
| | - Anatol Oleksijew
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Darren C. Phillips
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Brad E. Sleebs
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department
of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Brian J. Smith
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department
of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Morey L. Smith
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Stephen K. Tahir
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Keith G. Watson
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
- Department
of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Yu Xiao
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - John Xue
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Haichao Zhang
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Kerry Zobel
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 United States
| | - Saul H. Rosenberg
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Chris Tse
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Joel D. Leverson
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Steven W. Elmore
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| | - Andrew J. Souers
- AbbVie, Inc., 1 North Waukegan
Road, North Chicago, Illinois 60064 United States
| |
Collapse
|
48
|
Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Oncogenic protein interfaces: small molecules, big challenges. Nat Rev Cancer 2014; 14:248-62. [PMID: 24622521 DOI: 10.1038/nrc3690] [Citation(s) in RCA: 206] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Historically, targeting protein-protein interactions with small molecules was not thought possible because the corresponding interfaces were considered mostly flat and featureless and therefore 'undruggable'. Instead, such interactions were targeted with larger molecules, such as peptides and antibodies. However, the past decade has seen encouraging breakthroughs through the refinement of existing techniques and the development of new ones, together with the identification and exploitation of unexpected aspects of protein-protein interaction surfaces. In this Review, we describe some of the latest techniques to discover modulators of protein-protein interactions and how current drug discovery approaches have been adapted to successfully target these interfaces.
Collapse
Affiliation(s)
- Tracy L Nero
- Australian Cancer Research Foundation Rational Drug Discovery Centre and Biota Structural Biology Laboratory, St. Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3065, Australia
| | - Craig J Morton
- Australian Cancer Research Foundation Rational Drug Discovery Centre and Biota Structural Biology Laboratory, St. Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3065, Australia
| | - Jessica K Holien
- Australian Cancer Research Foundation Rational Drug Discovery Centre and Biota Structural Biology Laboratory, St. Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3065, Australia
| | - Jerome Wielens
- 1] Australian Cancer Research Foundation Rational Drug Discovery Centre and Biota Structural Biology Laboratory, St. Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3065, Australia. [2] Department of Medicine, University of Melbourne, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia
| | - Michael W Parker
- 1] Australian Cancer Research Foundation Rational Drug Discovery Centre and Biota Structural Biology Laboratory, St. Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3065, Australia. [2] Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3052, Australia
| |
Collapse
|
49
|
Roy MJ, Vom A, Czabotar PE, Lessene G. Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br J Pharmacol 2014; 171:1973-87. [PMID: 24117105 PMCID: PMC3976616 DOI: 10.1111/bph.12431] [Citation(s) in RCA: 87] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Revised: 09/13/2013] [Accepted: 09/18/2013] [Indexed: 12/27/2022] Open
Abstract
The principal biological role of mitochondria is to supply energy to cells; although intriguingly, evolution has bestowed another essential function upon these cellular organelles: under physiological stress, mitochondria become the cornerstone of apoptotic cell death. Specifically, mitochondrial outer membrane permeabilization (MOMP) allows cell death factors such as cytochrome c to be released into the cytoplasm, thus inducing caspase activation and the eventual destruction of essential cellular components. Proteins of the B-cell lymphoma 2 (BCL-2) family control the tightly regulated pathway that causes MOMP. The equilibrium between pro-survival and pro-apoptotic members of the BCL-2 family dictates the fate of cells, the homeostasis of organs and, by extension, the health of whole organisms. Dysregulation of this equilibrium is involved in a large number of diseases such as cancer, autoimmunity and neurodegenerative conditions. Modulating the activity of the BCL-2 family of proteins with small molecules or peptides is an attractive but challenging therapeutic goal. This review highlights the latest developments in this field and provides evidence that this strategy is likely to have a positive effect on the treatment of still poorly addressed medical conditions.
Collapse
Affiliation(s)
- M J Roy
- Divisions of Chemical and Structural Biology, The Walter and Eliza Hall Institute of Medical ResearchMelbourne, Vic, Australia
- Department of Medical Biology, The University of MelbourneMelbourne, Vic, Australia
| | - A Vom
- Divisions of Chemical and Structural Biology, The Walter and Eliza Hall Institute of Medical ResearchMelbourne, Vic, Australia
- Department of Medical Biology, The University of MelbourneMelbourne, Vic, Australia
| | - P E Czabotar
- Divisions of Chemical and Structural Biology, The Walter and Eliza Hall Institute of Medical ResearchMelbourne, Vic, Australia
- Department of Medical Biology, The University of MelbourneMelbourne, Vic, Australia
| | - G Lessene
- Divisions of Chemical and Structural Biology, The Walter and Eliza Hall Institute of Medical ResearchMelbourne, Vic, Australia
- Department of Medical Biology, The University of MelbourneMelbourne, Vic, Australia
- Department of Pharmacology and Therapeutics, The University of MelbourneMelbourne, Vic, Australia
| |
Collapse
|
50
|
Bumagin NA, Veselov IS, Belov DS. An Effective Activation of Palladium Phosphine Complexes in Aqueous Phase Reactions of Hetero-Aromatic Boronic Acids with Aryl Halides. Chem Heterocycl Compd (N Y) 2014. [DOI: 10.1007/s10593-014-1443-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|